CANBERA (dpa-AFX) - Telix Pharmaceuticals Limited (TLX, TLX.AX) reported that its group revenue for the first quarter of fiscal year 2016 increased about 24% to US$230 million, from US$186 million last year.
Precision Medicine revenue for the quarter were US$186 million, up 23% from prior year.
The company reaffirmed its revenue guidance for fiscal year 2026 in a range of US$950 million to US$970 million.
TLX.AX was trading at A$13.54 up A$0.59 or 4.56%.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
Copyright(c) 2026 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2026 AFX News



